Program EADA 2021

The program on 18 November consists of 3 building blocks. Registration for lectures in one or more of the various blocks is now open:

I: Setting the scene: Corporates, Authorities & globally active Organisations

II: Technology and Product Updates in AMR: Academia, Start-ups & SMEs

III: Accelerating AMR R&D: Initiatives to boost national / global AMR R&D

Preliminary program:

TIME:I: SETTING THE SCENE OF AMR R&DPresenting:Affiliation:
09:30
Welcome
Dr Maarten van DongenAMR Insights (Netherlands)
09:40
KEY NOTE LECTURE by MERCK / MSD: title to follow
TBC
Merck / MSD (USA, Netherlands)
10:00
iiCON: Delivering Solutions for Integrated Solutions in AMRDr Becky Jones-PhillipsLiverpool School of Tropical Medicine (UK)
10:20
– Coffee break –
10:30
10:50
Antimicrobial Resistance in Zambia: A Systematic Review
Dr Avis Nowbuth
Pan-African Organisation for Health Education and Research (USA)
11:10
To be communicated
Dr Maneesh Paul
Acharya Institutes (India)
11:30
11:50
12:10
12:30
Concluding remarks on the morning program
Dr Maarten van Dongen AMR Insights (Netherlands)
12:35
– Lunch break –
II: TECHNOLOGY AND PRODUCT UPDATES IN AMR
01:00
Use of bacteriophages in Animal Health
Dr Viviana Clavijo
Sciphage (Colombia)
01:20
A novel series of ruthenium antimicrobial compounds
Dr Kirsty Smitten
Metallobio (UK)
01:40
Two exciting late stage clinical assets and a range of earlier research programmes
Dr Daniel Hynes
Destiny Pharma (UK)
02:00
Tears hold a possibility to fight ABR
Dr Richard Stead
Qures Goup (UK)
02:20
A rapid, low cost, antibiotic susceptibility test for urinary tract infectionsDr Stuart Hannah
University of Strathclyde/ Microplate Dx (UK)
02:40
Novel non-pharmaceutical approach to prevent and control of bacterial infections without giving rise to AMRDr Vipula Tailor
Sonix Medical Devices, Inc (USA)
03:00
Fighting MDR Neisseria gonorrhoeae with novel massive polypharmacologyDr Pascal MayerAlphanosos (F)
03:20
Antimicrobial susceptibility prediction, using direct-from-sample whole genome sequencingDr Ronda Taylor
Day Zero Diagnostics (USA)
03:40
03:50
– Coffee break –
III: ACCELERATING AMR R&D
04:00
Supporting innovators to fight drug-resistant bacterial infections
Dr Douglas Haggstrom
INCATE (Switzerland)
04:20
Horizon Europe grants aimed at R&D projects in the space of AMR
Dr Vlad Grecu
Catalyze Group (Netherlands)
04:40

Creating a large collection of chemical matter specifically targeting Gram-negative antimicrobial drug discovery
Dr. Bruce Blough

CC4CARB / NIH NIAID (USA)

05:00
Delivering drug and/or diagnostic in the areas of Neglected Diseases
Dr Shridhar Narayanan
Foundation for Neglected Disease Research (India)
05:10
State-Of-The-Art Platform Technologies essential for success and leadership in the field of AMRDr Taslimarif SaiyedC-CAMP (India)
05:20JPIAMR-VRI a dynamic network of AMR research facilities to share and use resources and improve dialogue amongst researchers, funders and policy makersDr Shawon Lahiri

JPIAMR (EU)

05:40
Closing remarks
Dr Maarten van Dongen AMR Insights (Netherlands)
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!